Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Deepan S Dalal"'
Autor:
Griffin J. Reed, Deepan S. Dalal
Publikováno v:
SN Comprehensive Clinical Medicine. 4
Publikováno v:
Seminars in Arthritis and Rheumatism
Background Biologic disease modifying agents (bDMARDs) are an integral part of rheumatoid arthritis treatment guidelines but are associated with significant cost in the US. We present the trends in total spending and unit cost of conventional DMARDs
Autor:
Deepan S Dalal, Maureen Dubreuil, David T. Felson, Tuhina Neogi, Yuqing Zhang, Hyon K. Choi, Christine Peloquin
Publikováno v:
Rheumatol Int
OBJECTIVE: Certain non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with an increased risk of myocardial infarction (MI), a risk linked to cyclo-oxygenase-2 inhibition. There are limited studies assessing the risk of MI associated
Publikováno v:
Arthritis Care & Research. 72:1663-1664
Publikováno v:
JCR: Journal of Clinical Rheumatology. 27:S737-S738
Publikováno v:
Annals of the Rheumatic Diseases. 75:1595-1598
ObjectivesTo evaluate if optimal dose of either oral or injectable regimens of methotrexate (MTX) of 25 mg/week was used in the comparator arms of studies comparing biologic drugs with MTX in rheumatoid arthritis (RA).MethodsA systematic literature s
Autor:
Yuqing Zhang, David T. Felson, Hyon K. Choi, Na Lu, Maureen Dubreuil, Taeyeon Lee, Deepan S Dalal
Publikováno v:
Rheumatology. 55:1099-1105
Objective. We aimed to examine whether the current users of specific NSAIDs have an increased risk of venous thromboembolism (VTE) among knee OA patients. Methods. We conducted a population-based case-control study using The Health Improvement Networ
Publikováno v:
Annals of the Rheumatic Diseases. 79:1880.1-1881
Background:Emergency department (ED) visits for acute gout increased by approximately 20% between 2006 and 2014 in the United States. (1) Reducing ED length of stay (LOS) can help improve health outcomes, and reduce ED crowding and cost of care for p
Autor:
Rasha Alqadi, James L. Rudolph, Christopher W. Halladay, Alisha Lakhani, Deepan S Dalal, Josefina Durán, Tina Brar
Publikováno v:
Seminars in arthritis and rheumatism. 48(5)
Biologic anti-rheumatic drugs are used with less frequency among older patients compared to young patients. This population is less represented in studies performed to evaluate the efficacy and safety of this drugs. We aimed to assess the efficacy an
Autor:
Josefina Durán, James L. Rudolph, Tina Brar, Christopher W. Halladay, Alisha Lakhani, Deepan S Dalal, R Alqadi
Publikováno v:
Poster Presentations.
Background Rheumatoid arthritis (RA) patients are disproportionately older (33% >60 years). With improved biologic therapy for RA, there is a need to understand the efficacy and safety of biologic therapies in older RA (oRA) patients. Objectives To s